EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Tamara Y Milder iD, Leah Shepherd, Hans Kristian Raket iD, Jerry R Greenfield, Richard O Day iD, Jialing Lin iD, Juliana de Oliveira Costa, Sophie Stocker, Carol A Pollock, Brendon Neuen iD, Min Jun iD, Jane Ludington und 2 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Tamara Y Milder und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Intelligence Research Program, School of Population Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Hospitalization, Hypoglycemic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns: dipeptidyl peptidase‐4 inhibitors (DPP‐4i). Materials and Methods We conducted a retrospective new‐user cohort study using linked, population‐level data for adult residents of New South Wales, Australia. Adults aged ≥ 40 years initiating SGLT2i or DPP‐4i (separate cohorts) between 2016 and 2020 were followed until death, mid‐2021, or treatment discontinuation (gap of ≥ 90 days without a dispensing of the index medicine). We used Cox proportional hazards models to estimate the association between hospitalisation and discontinuation, adjusting for demographic and clinical characteristics. We treated the ‘hospitalisation period’ (the inpatient stay plus the 90 days following discharge) as a time‐dependent exposure.

Results

Among people initiating SGLT2i ( n = 106 098), the median age was 63 years and 61% were male. Overall, 35.1% were hospitalised during follow‐up, and discontinuation was substantially more frequent during the hospitalisation period (56.4 per 100 person‐years) compared with other follow‐up times (37.6 per 100 person‐years). This association remained significant after adjustment (HR: 1.83; 95% CI: 1.79–1.87). Similar patterns were observed among DPP‐4i treated people (HR: 1.55; 95% CI: 1.51–1.58).

Conclusions

Hospitalisation is a strong risk factor for discontinuation of SGLT2i and DPP‐4i therapy. Strategies to support re‐initiation of SGLT2i during transitions from hospital to community care are needed to prevent harm and maximise cardiorenal protective effects of these medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHospitalizationHypoglycemic AgentsHumansMaleRetrospective StudiesFemaleMiddle AgedRisk FactorsDipeptidyl-Peptidase IV InhibitorsAgedNew South WalesAdultDiabetic Ketoacidosis

Stichwörter der Autor:innen

DPP‐IV inhibitorSGLT2 inhibitorpharmaco‐epidemiologyreal‐world evidencetype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Medicines Intelligence Research Program, School of Population Health, University of New South Wales, Sydney, Australia.
  • School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.
  • St Vincent's & Mater Clinical School, School of Medicine, The University of Notre Dame, Sydney, Australia.
  • Department of Endocrinology, St Vincent's Hospital, Sydney, Australia.
  • Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Copenhagen Phase IV Unit, Department of Clinical Pharmacology and Center for Clinical Research and Prevention, University Hospital of Copenhagen-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

ORCID-Profile: Tamara Y Milder, Hans Kristian Raket, Richard O Day, Jialing Lin, Brendon Neuen, Min Jun, Michael O Falster

Zitieren

APA

Milder, T. Y., Shepherd, L., Raket, H. K., Greenfield, J. R., Day, R. O., Lin, J., de Oliveira Costa, J., Stocker, S., Pollock, C. A., Neuen, B., Jun, M., Ludington, J., Pearson, S. A., & Falster, M. O. (2026). Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71219

Vancouver

Milder TY, Shepherd L, Raket HK, Greenfield JR, Day RO, Lin J, et al. Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71219

BibTeX
@article{Milder2026,
  author = {Milder, Tamara Y and Shepherd, Leah and Raket, Hans Kristian and Greenfield, Jerry R and Day, Richard O and Lin, Jialing and de Oliveira Costa, Juliana and Stocker, Sophie and Pollock, Carol A and Neuen, Brendon and Jun, Min and Ludington, Jane and Pearson, Sallie-Anne and Falster, Michael O},
  title = {Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71219}
}
Kostenlos starten →